Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-39032
PROFOUND MEDICAL CORP.
(Exact Name of Registrant as Specified in its Charter)
Ontario, Canada
Not Applicable
(State or other jurisdiction ofincorporation or organization)
(I.R.S. EmployerIdentification No.)
2400 Skymark Avenue, Unit #6, Mississauga, Ontario, Canada(Address of principal executive offices)
L4W 5K5(Zip Code)
Registrant’s telephone number, including area code: (647) 476-1350
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Shares, No Par Value Per Share
PROF
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 5, 2026, the registrant had 36,626,844 common shares, no par value per share, outstanding.
EXPLANATORY NOTE
Profound Medical Corp. (the “Company”) qualifies as a “Foreign Private Issuer,” as defined in Rule 3b-4 under the Securities Exchange Act of 1934 (the “Exchange Act”) and is exempt from filing quarterly reports on Form 10-Q by virtue of Rules 13a-13 and 15d-13 under the Exchange Act. The Company has voluntarily elected to file this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
Form 10-Q – QUARTERLY REPORT
For the Quarter Ended September 30, 2026
Page
PART I.
Financial Information
Item 1.
Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets (Unaudited)
1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
2
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited)
3
Condensed Consolidated Statements of Cash Flows (Unaudited)
5
Notes to Condensed Consolidated Financial Statements
6
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
16
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
23
Item 4.
Controls and Procedures
PART II.
Other Information
Legal Proceedings
Item 1A.
Risk Factors
Unregistered Sales of Equity Securities and Use of Proceeds
Defaults Upon Senior Securities
24
Mine Safety Disclosures
Item 5.
Item 6.
Exhibits
Signatures
25
i
Profound Medical Corp.
CONDENSED CONSOLIDATED BALANCE SHEETS
(USD in thousands, except per share data)
(unaudited)
September 30,
December 31,
2026
2025
$
Assets
Current assets:
Cash
33,343
59,723
Trade and other receivables, net (note 3)
10,991
7,200
Inventory (note 4)
10,242
8,238
Prepaid expenses and deposits
253
928
Total current assets
54,829
76,089
—
300
Property and equipment, net (note 5)
430
698
Intangible assets, net (note 6)
115
138
Right-of-use assets, net (note 9)
2,687
184
Deferred tax assets, net
93
66
Total assets
58,154
77,475
Liabilities
Current liabilities:
Accounts payable
1,048
1,563
Accrued expenses and other current liabilities (note 7)
5,517
3,815
Deferred revenue
805
445
Long-term debt (note 8)
4,512
Lease liabilities (note 9)
105
213
Income tax payable
77
39
Total current liabilities
12,064
6,075
743
388
4,499
2,741
Other non-current liabilities
79
Total liabilities
15,641
11,041
Shareholders’ equity
Common shares, no par value, unlimited shares authorized, 36,626,844 and 36,293,640 issued and outstanding at September 30, 2026 and December 31, 2025, respectively (note 10)
326,108
323,839
Additional paid-in capital
25,256
25,310
Accumulated other comprehensive income
3,204
5,025
Accumulated deficit
(312,055)
(287,740)
Total shareholders’ equity
42,513
66,434
Total liabilities and shareholders’ equity
The accompanying notes are an integral part of these condensed consolidated financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Three Months Ended September 30,
Nine Months Ended September 30,
Revenue (note 12)
Recurring - non-capital
4,106
4,066
8,192
7,428
Capital equipment
5,724
1,223
9,458
2,693
9,830
5,289
17,650
10,121
Cost of sales
2,150
1,358
4,191
2,719
Gross profit
7,680
3,931
13,459
7,402
Operating expenses
Research and development
5,806
5,418
16,722
16,324
Selling, general and administrative
9,695
7,426
23,645
24,963
Total operating expenses
15,501
12,844
40,367
41,287
Operating loss
7,821
8,913
26,908
33,885
Other (income) expenses
Net finance income
(196)
(122)
(909)
(910)
Net foreign exchange (gain) loss
101
(935)
(1,760)
1,194
Total other (income) expenses
(95)
(1,057)
(2,669)
284
Net loss before income taxes
7,726
7,856
24,239
34,169
Income tax expense
8
100
103
219
Deferred tax (recovery) expense
(12)
21
(27)
7
Total income tax (recovery) expense
(4)
121
76
226
Net loss attributed to shareholders for the period
7,722
7,977
24,315
34,395
Other comprehensive (income) loss
Item that may be reclassified to (income) loss
Foreign currency translation adjustment
(134)
808
1,821
(2,008)
Net loss and other comprehensive loss for the period
7,588
8,785
26,136
32,387
Loss per share (note 13)
Basic and diluted net loss per common share
0.21
0.26
0.67
1.14
Basic and diluted weighted average common shares outstanding
36,556,064
30,104,497
36,402,550
30,119,569
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(USD in thousands)
Accumulated
Additional
Other
Paid-in
Comprehensive
Common Shares
Capital
Income
Deficit
Tota1
Shares
Amount $
Balance - December 31, 2025
36,293,640
Net loss for the period
(7,053)
Cumulative translation adjustment – net of tax of $nil
(1,005)
Vesting of DSUs (note 11)
10,000
68
(68)
Vesting of RSUs (note 11)
33,997
256
(256)
Share-based compensation (note 11)
Balance – March 31, 2026
36,337,637
324,163
26,034
4,020
(294,793)
59,424
(9,540)
(950)
16,128
96
(96)
178,829
1,124
(1,124)
874
Balance – June 30, 2026
36,532,594
325,383
25,688
3,070
(304,333)
49,808
(7,722)
134
6,668
58
(58)
79,833
612
(612)
Exercise of share options (note 11)
7,749
55
(19)
36
257
Balance – September 30, 2026
36,626,844
Total
Balance - December 31, 2024
30,039,809
281,552
21,298
2,742
(245,170)
60,422
(10,724)
13,333
89
(89)
989
Balance – March 31, 2025
30,053,142
281,641
22,198
2,845
(255,894)
50,790
(15,695)
2,713
1,451
Balance – June 30, 2025
23,649
5,558
(271,589)
39,259
(7,977)
(808)
132,115
1,036
(1,036)
8,335
74
(74)
1,669
Balance – September 30, 2025
30,193,592
282,751
24,208
4,750
(279,566)
32,143
4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Cash flows from operating activities
(24,315)
(34,395)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment (note 5)
345
311
Amortization of intangible assets (note 6)
140
Non-cash lease expense adjustment
148
(28)
2,179
4,109
Interest and accretion expense
12
Changes in operating assets and liabilities:
Trade and other receivables (note 3)
(3,867)
(908)
(2,444)
(2,593)
661
1,158
Accounts payable, accrued expenses and other liabilities (note 7)
1,555
338
766
Income taxes payable
40
Deferred tax assets
(30)
10
Net cash used in operating activities
(24,927)
(31,641)
Cash flows from financing activities
Repayments of long-term debt (note 8)
(290)
Proceeds from the exercise of stock options (note 11)
Net cash provided by (used in) financing activities
Net decrease in cash
(24,891)
(31,931)
Effect of exchange rate changes on cash
(1,489)
1,845
Cash, beginning of period
54,912
Cash, end of period
24,826
Supplemental cash flow information:
Interest paid
227
251
Income taxes paid, net of refunds received
63
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1Description of business
Profound Medical Corp. (Profound) (the Company) was incorporated under the Ontario Business Corporations Act on July 16, 2014. The Company is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing platform technologies.
The Company’s registered address is 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, Canada, L4W 5K5.
Summary of significant accounting policies
Basis of preparation
The Company prepares its condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP). The condensed consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.
Unaudited condensed consolidated financial statements
The condensed consolidated balance sheet as of September 30, 2026, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025, the condensed consolidated statements of shareholders’ equity for the three and nine months ended September 30, 2026 and 2025, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025, are unaudited. The financial data and other information disclosed in these notes to the consolidated financial statements related to September 30, 2026, and the three and nine months ended September 30, 2026 and 2025, are also unaudited. The accompanying condensed consolidated balance sheet as of December 31, 2025, has been derived from the audited consolidated financial statements included in the Annual Report on Form 10-K (“Annual Report”) filed with the Securities and Exchange Commission on March 5, 2026.
The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to a fair statement of the Company’s financial position as of September 30, 2026, and the results of its operations and cash flows for the three and nine months ended September 30, 2026 and 2025. The results for the three and nine months ended September 30, 2026, are not necessarily indicative of results to be expected for the year ending December 31, 2026, or for any other period or for any future year and should be read in conjunction with the annual consolidated financial statements included in the Annual Report.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the allocation of transaction prices and timing of revenue recognition, assumptions related to the determination of expected credit losses, and the valuation of stock options. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Recent Accounting Pronouncements
In January 2026, the Company adopted ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The Company elected the practical expedient to assume that current conditions as of the balance-sheet date remain unchanged for the remaining life of its current accounts receivable and contract assets. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements.
Trade and other receivables, net
Trade receivables and other receivables, net, as of September 30, 2026 and December 31, 2025 consists of the following:
Trade receivables, gross
11,681
7,621
Contract assets, gross
386
Trade receivables and contract assets
8,007
Allowance for expected credit losses
(1,185)
(898)
Trade receivables, net
10,496
7,109
Tax receivables
412
Other receivables
83
80
Total trade and other receivables, net
7,500
Less: Current portion
Long-term portion
The activity in the allowance for expected credit losses for trade receivables and contract assets was as follows:
Balance - Beginning of the period
898
158
Write off against the allowance
(375)
Provision for allowance for expected credit losses
662
740
Balance - End of the period
1,185
Inventory
Inventory as of September 30, 2026 and December 31, 2025 consists of the following:
Finished goods
5,295
5,280
Raw materials
4,947
2,958
During the three and nine months ended September 30, 2026, $2,039 and $3,900, respectively (three and nine months ended September 30, 2025 - $1,275 and $2,431, respectively) of inventory was recognized in cost of sales.
Property and equipment, net
The major components of property and equipment, net, as of September 30, 2026 and December 31, 2025 consist of the following:
Leasehold improvements
542
Equipment
176
Equipment under operating lease
1,422
1,571
2,140
2,289
Accumulated depreciation
(1,710)
(1,591)
Depreciation expense for the three and nine months ended September 30, 2026 was $126 and $345, respectively (three and nine months ended September 30, 2025 - $93 and $311, respectively). During the three and nine months ended September 30, 2026, the Company sold $72 and $226, respectively (three and nine months ended September 30, 2025 - $387 and $600, respectively) of equipment under operating lease to a customer.
Intangible assets
The major components of intangible assets as of September 30, 2026 and December 31, 2025 consist of:
September 30, 2026
December 31, 2025
Weighted
Average
Remaining
Useful
Gross
Amortization
Net
Lives
Carrying
and
(Years)
Amount
Impairments
Exclusive license agreement
2.9
231
(176)
(158)
73
Software
978
(978)
Distribution rights
14.1
(6)
60
(1)
65
1,275
(1,160)
(1,137)
The Company has a license agreement (the license) with Sunnybrook Health Sciences Centre (Sunnybrook), pursuant to which Sunnybrook licenses to the Company certain intellectual property and exclusively licensed-in rights that enable the Company to use Sunnybrook’s technology for MRI-guided trans-urethral ultrasound therapy. The Company has the option to acquire rights to improvements to the relevant technology and intellectual property. If the Company fails to comply with any of its obligations or otherwise breaches this agreement, Sunnybrook may have the right to terminate the license.
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities, as of September 30, 2026 and December 31, 2025 consist of the following:
Accrued employee compensation
3,329
2,347
Clinical trials
728
524
Other general accruals
1,460
944
Long-term debt
On March 3, 2025, the Company entered into an amended and restated credit agreement (the “CIBC Credit Agreement”), with Canadian Imperial Bank of Commerce (“CIBC”) which amended the terms of the CIBC Loan and the existing long-term debt provided under the Original CIBC Credit Agreement was repaid with proceeds from a new revolving line of credit provided by CIBC to Profound. This was accounted for as a modification of debt whereby a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. The line of credit bears interest at the Wall Street Journal Prime Rate subject to a floor of 6.25%. Following an amendment to the CIBC Credit Agreement on September 30, 2025, the amended financial covenants are that unrestricted cash is at all times the greater of: (i) to the extent that EBITDA is a negative number or loss for the most recent six-month period, the amount of such loss, or (ii) $10,000, reported on a monthly basis and that revenue for the 12 month period must be 15% greater than revenue for the same period in the prior fiscal year, reported on a quarterly basis. The Company is in compliance with these financial covenants as of September 30, 2026. Future compliance with the financial covenants included in the CIBC Credit Agreement is dependent upon achieving certain revenue, EBITDA, and anticipated unrestricted cash levels.
The obligations are secured by, inter alia, a general security agreement over the assets and the assets of the Company’s subsidiaries. The revolving line of credit matures on March 3, 2027 and provides that Profound may request a one-time increase in the principal amount of the revolving line of credit up to a maximum amount of $10,000, which is subject to the approval of CIBC in its sole discretion.
Balance - Beginning of period
4,661
Interest expense
239
394
(227)
(331)
Foreign exchange
Repayment
Balance - End of period
9
Leases
Leases where the Company is the Lessee
The Company leases certain office premises. In January 2026, the Company entered into a lease modification agreement for one of its office premises that extended the lease term and modified the payment schedule. This modification did not provide the Company with the right to use any additional underlying assets and therefore was accounted for as a modification of an existing operating lease, resulting in a remeasurement of the related operating lease liability using an updated incremental borrowing rate and a corresponding adjustment to the right‑of‑use asset. The extension commenced October 1, 2026, with fixed payment structures expiring in 2033. Lease liabilities and corresponding right-of-use assets were recognized based on the present value of future lease payments.
Lease expense for the three and nine months ended September 30, 2026 and 2025:
Operating lease costs
116
Total lease costs
353
179
Other information related to operating leases is as follows:
Cash paid from operating cash flows for amounts included in the measurement of lease liabilities
214
212
Weighted average remaining lease term
7.00 years
0.75 years
Weighted average discount rate
5.50
%
5.99
Maturities of the operating lease liabilities and minimum payments for operating leases having initial or remaining noncancellable terms in excess of one year as of September 30, 2026 were as follows:
2027
378
2028
498
2029
513
2030
529
Thereafter
1,535
3,453
Less: Imputed interest
607
Present value of remaining lease payments
2,846
Non-current portion
Share capital
Common shares
The Company is authorized to issue an unlimited number of common shares.
Issued and outstanding (with no par value)
36,626,844 (December 31, 2025 – 36,293,640) common shares
Voting Power
Except as otherwise required by law, the holders of common shares possess all voting power for the election of the Company’s directors and all other matters requiring shareholder action. Holders of common shares are entitled to one vote per share on matters to be voted on by shareholders.
Dividends
Holders of common shares will be entitled to receive such dividends, if any, as may be declared from time to time by the Company’s board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.
Liquidation, Dissolution and Winding Up
In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to shareholders, after the rights of the creditors have been satisfied.
11
Share-based payments
Share options
Effective May 20, 2020, the Company adopted amendments to the share option plan (the Share Option Plan). The aggregate maximum number of common shares that may be issued under the Share Option Plan, together with all other security-based compensation arrangements of the Company, is limited to 13% of the issued and outstanding common shares. The current maximum number of common shares reserved for issuance under the share option plan together with the long-term incentive plan is 4,761,489 common shares (or such other number as may be approved by the holders of the voting shares of the Company).
As of September 30, 2026, 2,748,199 (December 31, 2025 – 2,142,522) options were outstanding. Each share option granted allows the holder to purchase one common share, at an exercise price not less than the lesser of the closing trading price of the common shares on the TSX (or other exchange where the common shares are listed), on the date a share option is granted and the volume-weighted average price of the common shares for the five trading days immediately preceding the date the share option is granted. Share options granted under the Share Option Plan generally have a maximum term of ten years and vest over a period of up to four years.
A summary of the share option activity during the period presented and the total number of share options outstanding as of those dates are set forth below:
Weighted average
Number
exercise price
of options
C$
2,142,522
13.53
Granted
1,024,150
9.59
Exercised
(7,749)
6.39
Forfeited/expired
(410,724)
12.67
Balance - September 30, 2026
2,748,199
12.21
Exercisable - September 30, 2026
1,375,249
14.38
Expected to vest - September 30, 2026
The Company estimated the fair value of the share options granted during the period using the Black-Scholes option pricing model with the weighted average assumptions below. The Company estimated the expected future stock price volatility for its common stock by using its historical volatility based on daily price observations for the most recent historical period equal to the length of the instrument’s expected life of options.
March 17,
May 19,
June 11,
September 17,
Grant date
Exercise price
C$7.58
C$9.63
C$9.41
C$9.76
Expected volatility
67
Expected life of options
6 years
Risk-free interest rate
3.00
3.45
3.32
3.24
Dividend yield
The weighted average grant date fair values of share options granted for the three and nine months ended September 30, 2026 were C$4.85 and C$4.92, respectively (three and nine months ended September 30, 2025 - C$4.17 and C$4.55).
Long-term incentive plan
Effective May 17, 2023, the Company adopted the amended long term incentive plan (the LTIP). The LTIP is an incentive-based equity compensation plan that provides for the grant of restricted share units (the RSUs) and deferred share units (the DSUs, together with the RSUs, the Units). The aggregate maximum number of common shares that may be reserved for issuance under the LTIP in respect of grants of RSUs and DSUs is limited to 4.9% of the issued and outstanding common shares on a non-diluted basis, provided that, the maximum number of common shares which may be reserved for issuance pursuant to all of the Company’s security-based compensation arrangements shall not in the aggregate exceed 13% of the issued and outstanding common shares on a non-diluted basis. The Company may grant RSUs to officers, directors, employees, or consultants of the Company or any of its affiliates and any such person’s personal holding company, as designated by the Board in a resolution upon the terms and conditions set forth in a grant agreement. DSUs may be granted to any director of the Company who has been designated by the Company for participation in the LTIP and who has agreed to participate in the LTIP. Each Unit represents the right to receive one common share in accordance with the terms of the LTIP. The number of Units granted at any particular time will be calculated by dividing the dollar amount of such grant by the market value of a common share on the applicable grant date, which is equal to the volume weighted average trading price of all common shares traded on the TSX (or other exchange where the common shares are listed) for the five trading days immediately preceding such date. RSUs and DSUs granted under the LTIP vest over a period of up to three years, subject to DSU deferral features.
The following table summarizes RSUs activities:
average grant
date fair value
Number of
per share
RSUs
859,335
9.23
732,930
8.24
Vested
(292,659)
9.62
Forfeited
(205,005)
8.70
1,094,601
8.56
A summary of the DSUs changes during the period are set forth below:
DSUs
135,490
9.39
51,324
9.36
(32,796)
9.56
(17,098)
9.37
136,920
9.34
Share-based compensation expense
The following table presents the components and classification of share-based compensation recognized for share options, RSUs, and DSUs for the three and nine months ended September 30, 2026 and 2025:
(47)
686
600
1,444
217
846
1,421
1,715
87
137
950
Share-based compensation
(15)
19
109
398
531
986
144
1,262
1,663
3,104
Revenue
The following table provides information about disaggregated revenue by products and services:
Timing of transfer of control
Point in time revenue
9,606
5,096
Service revenue recognized over time
224
193
17,046
9,571
604
550
13
Loss per share
The following table shows the calculation of basic and diluted loss per share:
Weighted average number of common shares
Basic and diluted loss per share
The computation of diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect of the share options, RSUs and DSUs. Of the 2,748,199 (September 30, 2025 – 2,149,479) share options, 1,094,601 (September 30, 2025 – 963,005) RSUs, and 136,920 (September 30, 2025 – 143,820) DSUs that are not included in the calculation of diluted loss per share for the period ended September 30, 2026, 1,375,249 (September 30, 2025 – 1,170,100) were exercisable.
14
Segment reporting
The Company’s operations are categorized into one industry segment, which is medical technology focused on magnetic resonance guided ablation procedures for the treatments to ablate the prostate gland, uterine fibroids, osteoid osteoma and nerves for palliative pain relief for patients with metastatic bone disease. The CODM, which is the Company’s Chief Executive Officer, regularly reviews the operating results of the Company on a consolidated basis as part of making decisions for allocating resources and evaluating performance. Further, the CODM is regularly provided with the consolidated expenses as noted on the consolidated statements of operations and comprehensive loss.
The following tables represent total revenue by geographic area, based on the location of the reporting entity for the three months ended September 30, 2026 and 2025, respectively:
For the three months ended September 30, 2026
Canada
USA
Germany
1,440
2,052
614
3,441
1,466
817
4,881
3,518
1,431
For the three months ended September 30, 2025
119
3,779
168
5,002
For the nine months ended September 30, 2026
3,054
4,192
946
5,954
9,008
6,879
1,763
For the nine months ended September 30, 2025
495
6,399
534
570
2,123
1,065
8,522
The following tables represent other geographic information for the nine months ended September 30, 2026 and the year ended December 31, 2025:
For the period ended September 30, 2026
China
Finland
46,007
7,257
1,884
2,906
Property and equipment
285
145
Right-of-use assets
Amortization of intangible assets
Depreciation of property and equipment
43
272
30
For the year ended December 31, 2025
63,046
9,791
1,243
3,258
41
481
187
51
322
373
15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
As used in this Quarterly Report on Form 10-Q, the “Company”, the “Registrant”, “we” or “us” refer to Profound Medical Corp. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in the Risk Factors section of the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2026, and elsewhere in this report under “Part II, Other Information—Item 1A, Risk Factors.” Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Unless stated otherwise, all references to “$” are to United States dollars in thousands and all references to “C$” are to Canadian dollars in thousands.
Overview
We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue utilizing our platform technologies and leveraging the healthcare system’s existing imaging infrastructure. Our lead product (the “TULSA-PRO system”) combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and capital equipment that are used in conjunction with a customer’s existing MRI scanner.
We are commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for pixel-by-pixel precision to preserve prostate disease patients’ urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57°C). TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is generally no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
We are also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. We are in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Results of Operations
Comparison of Three and Nine Months Ended September 30, 2026 and 2025
The following selected financial information as of and for the three and nine months ended September 30, 2026 and 2025 have been derived from the unaudited consolidated financial statements and should be read in conjunction with those unaudited consolidated financial statements and related notes.
For the nine months ended September 30,
Other (income) expense
For the three months ended September 30,
Change
4,541
86
792
3,749
95
Gross margin
78
Expenses
2,269
31
2,657
Net finance (income) expense
61
(111)
Total other (income) expense
962
(91)
(130)
(2)
Income taxes
(125)
(103)
(255)
(3)
Item that may be reclassified to profit or loss
(942)
(117)
(1,197)
(14)
(0.05)
17
7,529
1,472
54
6,057
82
(1,318)
(5)
(920)
0
(2,954)
(247)
(2,953)
(1,040)
(9,930)
(29)
(150)
(66)
(10,080)
3,829
(191)
(6,251)
(0.47)
(41)
Key Components of Our Results of Operations
We deploy a hybrid revenue business model in the United States to market TULSA-PRO by charging for the system separately as capital and an additional charge for the one-time-use devices. The Sonalleve product is marketed primarily outside North America deploying a one-time capital sales model with limited recurring service revenue. Outside of North America, we generate most of our revenues from our system sales (both TULSA-PRO and Sonalleve) in Europe and Asia where we deploy a hybrid business model, charging for the system separately as capital and an additional charge for the one-time-use devices. Revenue is comprised of (a) recurring – non-capital revenue, which consists of the sale of one-time-use devices and services associated with maintenance contracts and (b) capital equipment, which is the one-time sale of capital equipment and the lease of capital equipment.
For the three months ended September 30, 2026, we recorded revenue totaling $9,830, consisting of $5,724 from the one-time sale of capital equipment and $4,106 from recurring – non-capital revenue. For the three months ended September 30, 2025, we recorded revenue of $5,289, consisting of $1,223 from the one-time sale of capital equipment and $4,066 from recurring – non-capital revenue. The increase of $4,541, or 86%, in revenue for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was the result of higher capital sales overseas and within the United States during the third quarter of 2026.
18
For the nine months ended September 30, 2026, we recorded revenue totaling $17,650, consisting of $9,458 from the one-time sale of capital equipment and $8,192 from recurring – non-capital revenue. For the nine months ended September 30, 2025, we recorded revenue of $10,121, consisting of $2,693 from the one-time sale of capital equipment and $7,428, from recurring – non-capital revenue. The increase of $7,529, or 74%, in revenue for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 was driven by higher capital sales as well as recurring revenue.
Cost of Sales
Cost of sales primarily includes the cost of finished goods, depreciation of equipment under lease, inventory write-downs, royalties, warranty expenses, freight and direct overhead and labor expenses necessary to acquire or manufacture the finished goods.
For the three months ended September 30, 2026, we recorded a cost of sales of $2,150, related to the sale of medical devices, capital and non-capital, which reflects 78% gross margin. For the three months ended September 30, 2025, we recorded a cost of sales of $1,358, which reflects a 74% gross margin. The increase of $792, or 58%, in cost of sales for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was the result of increase in volume of sale of capital systems, which contains a higher margin and continued strong price discipline. The gross profit was higher in the three months ended September 30, 2026 by $3,749, or 95%, due to growth in the number of capital systems sold.
For the nine months ended September 30, 2026, we recorded a cost of sales of $4,191, related to the sale of medical devices, capital and non-capital, which reflects a 76% gross margin. For the nine months ended September 30, 2025, we recorded a cost of sales of $2,719, which reflects a 73% gross margin. The increase of $1,472, or 54%, in cost of sales for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 was the result of a different product combination whereby more capital equipment was sold which contains a higher margin and continued strong price discipline. The gross profit was higher in the nine months ended September 30, 2026 by $6,057, or 82%, due to growth in the number of capital systems sold.
Operating Expenses
Operating expenses consist of two components: research and development (“R&D”) and selling, general and administrative (“SG&A”).
R&D Expenses
R&D expenses are comprised of costs incurred in performing R&D activities, including new product development, continuous product improvement, investment in clinical trials and related manufacturing costs, materials and supplies, salaries and benefits, consulting fees, patent procurement costs, and occupancy costs related to R&D activity.
For the three months ended September 30, 2026, R&D expenses increased by $388, or 7%, to $5,806 compared to $5,418 for the three months ended September 30, 2025. The increase in R&D expenses was largely due to increased personnel-related expenses, including higher headcount, travel expenditures and higher consulting and material expenditures due to R&D initiatives to reduce product costs and improve efficiencies and predictability of our products and supply chain.
For the nine months ended September 30, 2026, R&D expenses increased by $398, or 2%, to $16,722 compared to $16,324 for the nine months ended September 30, 2025. The increase in R&D expenses was largely due to increased personnel-related expenses, including higher headcount, travel expenditures and higher consulting and material expenditures due to R&D initiatives to reduce product costs and improve efficiencies and predictability of our products and supply chain. Offsetting these costs were a reduction in clinical trial costs due to CAPTAIN trial enrollment completion.
These expenses emphasize our commitment to the ongoing development and improvement of the products while further demonstrating the commitment to a reliable and customizable product.
SG&A expenses
Selling, general and administrative expenses are comprised of business development costs related to the market development activities and commercialization of our systems, including salaries and benefits, marketing support functions, occupancy costs, insurance, various management and administrative support functions and other miscellaneous marketing and management costs.
SG&A expenses for the three months ended September 30, 2026 increased by $2,269, or 31%, to $9,695 compared to $7,426 for the three months ended September 30, 2025. The increase in SG&A was primarily due to increased commission expenses driven by our revenue growth, consulting fees for recruitment, severance expense, as well as an increase in promotion and marketing expenses to support our revenue.
SG&A expenses for the nine months ended September 30, 2026 decreased by $1,318, or 5%, to $23,645 compared to $24,963 for the nine months ended September 30, 2025. The decrease in SG&A was primarily due to decreased personnel-related expenses, including share based compensation and lower wages, and an overall discount in our insurance premiums for the same coverage from the prior year. Offsetting these expenses was an increase in consulting fees for recruitment as well as an increase in promotion and marketing expenses.
Net finance income is primarily comprised of the following: (i) the CIBC Credit Agreement (as defined herein) accreting to the principal amount repayable and its related interest expense; and (ii) interest income from cash.
Net finance income increased by $74 to ($196) during the three months ended September 30, 2026, compared to ($122) during the three months ended September 30, 2025. The increase in net finance income was primarily due to an increase in interest income from cash.
Net finance income decreased by $1 to ($909) during the nine months ended September 30, 2026, compared to ($910) during the nine months ended September 30, 2025. Net finance income remained substantially consistent with the prior-year period.
Net foreign exchange (gain) loss is primarily comprised of the change in the foreign exchange rates for the Company’s foreign currency denominated cash, trade receivables and accounts payable.
Net foreign exchange (gain) loss increased by $1,036 to $101 during the three months ended September 30, 2026, compared to ($935) during the three months ended September 30, 2025. The increase in net foreign exchange (gain) loss was primarily due to exposure changes and a decrease in the EUR and CAD currency rates.
Net foreign exchange (gain) loss decreased by $2,954 to ($1,760) during the nine months ended September 30, 2026, compared to $1,194 during the nine months ended September 30, 2025. The decrease in net foreign exchange (gain) loss was primarily due to an increase in the EUR and CAD currency rates.
Liquidity and Capital Resources
As of September 30, 2026, we had cash of $33,343 compared to $59,723 as of December 31, 2025. Historically, our primary source of cash has been financing activities, e.g., equity offerings as well as the CIBC Loan (as defined below).
Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of these unaudited consolidated financial statements. During that time, we expect that our expenses will increase, primarily due to the continued commercialization of TULSA-PRO and Sonalleve. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.
20
Use of Proceeds
2025 Offering and non-brokered private placement
We received net proceeds of $40,801 from the public offering and the private placement (together, the “2025 Offering”) completed in December 2025. We intend to use net proceeds from the 2025 Offering to fund the continued commercialization of the TULSA-PRO system in the United States, the continued development and commercialization of the TULSA-PRO system and the Sonalleve system globally and for working capital and general corporate purposes. In addition, there have been no material adjustments to the cost or timing of the business objective previously disclosed in such prospectus supplement.
Total spending of proceeds
from the 2025
Offering as of
TULSA-PRO commercialization
28,267
Sonalleve development and commercialization
5,856
Working capital and general corporate purposes
6,678
40,801
CIBC Loan
On March 3, 2025, we entered into an amended and restated credit agreement (the “CIBC Credit Agreement”) with Canadian Imperial Bank of Commerce (“CIBC”), which amended the terms of the loan with CIBC (the “CIBC Loan”) and the existing long-term debt provided under the original credit agreement with CIBC was repaid with proceeds from a new revolving line of credit provided by CIBC to us. The line of credit bears interest at the Wall Street Journal Prime Rate subject to a floor of 6.25%. Following an amendment to the CIBC Credit Agreement on September 30, 2025, the amended financial covenants are that unrestricted cash is at all times the greater of: (i) to the extent that EBITDA is a negative number or loss for the most recent six-month period, the amount of such loss, or (ii) $10,000, reported on a monthly basis and that revenue for the 12 month period must be 15% greater than revenue for the same period in the prior fiscal year, reported on a quarterly basis. We are in compliance with these financial covenants as of September 30, 2026. Future compliance with the financial covenants included in the CIBC Credit Agreement is dependent upon achieving certain revenue, EBITDA, and anticipated unrestricted cash levels.
The obligations are secured by, inter alia, a general security agreement over our assets and the assets of our subsidiaries. The revolving line of credit matures on March 3, 2027 and provides that we may request a one-time increase in the principal amount of the revolving line of credit up to a maximum amount of $10,000, which is subject to the approval of CIBC in its sole discretion.
Cash Flows
The following table summarizes our cash flows for each of the periods presented (in thousands):
Nine months ended September 30,
Cash provided by (used in) operating activities
Cash provided by (used in) financing activities
Foreign exchange on cash
Net increase (decrease) in cash
(26,380)
(30,086)
Operating Activities
Net cash used in operating activities for the nine months ended September 30, 2026 was $(24,927), primarily attributable to a net loss of $24,315 and $3,319 in net operating assets and liabilities, partially offset by $2,707 of non-cash charges. The cash used in operating activities was primarily due to the increased efforts supporting the commercialization and expansion of our products which resulted in an increase in marketing and promotion fees. Non-cash charges consisted primarily of share-based compensation, amortization and depreciation.
Net cash used in operating activities for the nine months ended September 30, 2025 was $(31,641). The principal use of the operating cash flows during the period related to a net loss of $34,395 and a change in net operating assets and liabilities of $(1,836) and in non-cash charges of $4,590. The cash used in operating expenses was primarily due to the increased efforts supporting the commercialization and expansion of our products. This resulted in an increase in headcount, travel, clinical trial costs and marketing fees. Non-cash charges consisted primarily of share-based compensation, amortization and depreciation.
Financing Activities
Net cash provided by (used in) financing activities for the nine months ended September 30, 2026 was $36 from the exercise of share options.
Net cash provided by (used in) financing activities for the nine months ended September 30, 2025 was $(290) from the repayments of long-term debt principal.
Foreign Exchange on Cash
Cash was impacted by the change in the foreign exchange rates for the Company’s foreign currency denominated cash. The value of our currencies decreased, resulting in a decrease in our cash holdings.
Funding Requirements
Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of these unaudited consolidated financial statements. During that time, we expect that our expenses will increase, primarily due to the continued commercialization of TULSA-PRO and Sonalleve.
We manage liquidity risk by monitoring actual and projected cash flows. A cash flow forecast is performed regularly to ensure that we have sufficient cash to meet our operational needs while maintaining sufficient liquidity. Our cash requirements depend on numerous factors, including market acceptance of our products, the resources devoted to developing and supporting the products and other factors. We expect to continue to devote substantial resources to expand procedure adoption and acceptance of our products.
We may require additional capital to fund R&D activities and any significant expansion of operations. Potential sources of capital could include equity and/or debt financings, development agreements or marketing agreements, the collection of revenue resulting from future commercialization activities and/or new strategic partnership agreements to fund some or all costs of development. There can be no assurance that we will be able to obtain the capital sufficient to meet any or all of our needs. The availability of equity or debt financing will be affected by, among other things, the results of R&D, our ability to obtain regulatory approvals, the market acceptance of our products, the state of the capital markets generally, strategic alliance agreements and other relevant commercial considerations. In addition, if we raise additional funds by issuing equity securities, existing security holders will likely experience dilution, and any incurring of indebtedness would result in increased debt service obligations and could require us to agree to operating and financial covenants that would restrict operations. Any failure on our part to raise additional funds on terms favorable to us or at all may require us to significantly change or curtail current or planned operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated, and could result in us not being in a position to take advantage of business opportunities, in the termination or delay of clinical trials for our products, in curtailment of product development programs designed to identify new products, in the sale or assignment of rights to technologies, product and/or an inability to file market approval applications at all or in time to competitively market products.
Critical Accounting Policies and Estimates
There have been no significant changes to our critical accounting policies since December 31, 2025. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements, refer to Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report on Form 10-K dated March 5, 2026.
22
See Note 2 to our Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures.
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2026, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. You should read this description of our controls and procedures together with “Item 9A. Controls and Procedures” included in our Annual Report on Form 10-K, which was filed with the SEC on March 5, 2026.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting, as identified in connection with evaluation required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that occurred during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.
Item 1A. Risk Factors.
Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows, and prospects. These risks are discussed more fully in the section entitled “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 5, 2026 (the “2025 Annual Report”). There have been no material changes to the risk factors described in the 2025 Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
Item 4. Mine Safety Disclosures.
Item 5. Other Information.
Rule 10b5-1 Trading Plans
During the three months ended September 30, 2026, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.
Item 6. Exhibits.
Exhibit Number
Exhibit Description
Filed with this Report
Incorporated by Reference herein from Form or Schedule
Filing Date
SEC File/Reg. Number
3.1
Articles of Incorporation
Form S-8(Exhibit 4.1)
11/7/2019
333-234574
3.2
Articles of Amendment
Form S-8(Exhibit 4.2)
3.3
Articles of Amalgamation
Form S-8(Exhibit 4.3)
3.4
Bylaws
Form S-8(Exhibit 4.4)
10.1#
Employment Agreement, dated as of September 1, 2026, by and between Profound Medical Corp. and Richard R. Fabian
X
10.2#*
Mutual Separation Agreement, dated August 14, 2026, by and between Profound Medical Corp. and Rashed Dewan
10.3#*
Contractor Services Agreement, dated August 14, 2026, by and between Profound Medical Corp. and Rashed Dewan
10.4‡*
Supply and Distribution Agreement, effective as of October 23, 2026, by and between Profound Medical (U.S.) Inc. and Cook Medical Holdings LLC
Form 8-K(Exhibit 10.1)
11/3/2026
001-39032
31.1
Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32†
Certification of the Company’s Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
† The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.
# Indicates a management contract or compensatory plan or arrangement.
‡ Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
* Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 5, 2026
By:
/s/ Arun Menawat
Name: Arun Menawat
Title: Chief Executive Officer
(Principal Executive Officer)
/s/ Matthew Sobczyk
Name: Matthew Sobczyk
Title: Chief Financial Officer
(Principal Financial and Accounting Officer)